Place of probiotics in the prevention and treatment of antibiotic-associated diarrhea


Cite item

Full Text

Abstract

The paper gives data on the prevalence and etiopathogenesis of antibiotic-associated diarrhea and describes the major pathogens of this disease and methods for their diagnosis. It considers treatment policy in detail, with an emphasis on the use of probiotics for both the prevention and therapy of the disease described. Russian investigations on the alleged topic of a Linex probiotic complex, as well as the authors’ original trial of this medication are presented.

About the authors

E Yu Plotnikova

Yu V Zakharova

References

  1. Самсонов А.А., Плотникова Е.Ю., Андреев Н.Г., Краснова М.В., Баранова Е.Н. Синдром раздраженного кишечника — болезнь со многими неизвестными, некоторые терапевтические аспекты. Лечащий врач 2012; 12: 34—39.
  2. Bartlett J.G. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334—339.
  3. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998; 16: 292—307.
  4. Surawicz C.M. Antibiotic-associated diarrhea and pseudomembranous colitis: are they less common with poorly absorbed antimicrobials? Chemotherapy 2005; 51 (Suppl. 1): 81—89.
  5. Bartlett J.G. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15: 573—581.
  6. Gilbert D.N. Aspects of the safety profile of oral antimicrobial agents. Infect Dis Clin Pract 1995; 4 (Suppl 2): 103—112.
  7. Плотникова Е.Ю., Захарова Ю.В. Роль пробиотиков в профилактике и лечении антибиотик-ассоциированной диареи. Доказательная гастроэнтерология 2013; 4 (2): 51—57.
  8. Шевяков М.А. Антибиотик-ассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия 2004; 10 (49): 26—29.
  9. McFarland L.V. Normalflora: Diversity and functions. Microb Ecol Health Dis 2000; 12: 193—207.
  10. Modi N., Wilcox M.H. Evidence of antibiotic induced Clostridium perfringens diarrhoea. J Clin Pathol 2001; 54: 748—751.
  11. Vaishnavi C., Kaur S., Singh K. Clostridium perfringens type A & antibiotic associated diarrhoea. Indian J Med Res 2005; 122: 52—56.
  12. Gravet A., Rondeau M., Harf-Monteil C., Grunenberger F., Monteil H., Scheftel J.M., Prevost G. Predominant Staphylococcus aureus isolated from antibiotic-associated diarrhea is clinically relevant and produces enterotoxin A and the bicomponent toxin LukE-LukD. J Clin Microbiol 1999; 37: 4012—4019.
  13. Beaugerie L., Metz M., Barbut F., Bellaiche G., Bouhnik Y., Raskine L., Nicolas J.C., Chatelet F.P., Lehn N., Petit J.C. Klebsiella oxytoca as an agent of antibiotic-associated hemorrhagic colitis. Clin Gastroenterol Hepatol 2003;1: 370—376.
  14. Kim S.W., Peck K.R., Jung S.I., Kim Y.S., Kim S.M., Lee N.Y., Song J.H. Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea. J Korean Med Sci 2001; 16: 742—744.
  15. Levine J., Dykoski R.K., Janoff E.N. Candida-associated diarrhea: a syndrome in search of credibility. Clin Infect Dis 1995; 21: 881—886.
  16. Song H.J., Shim K.N., Jung S.A, Choi H.J., Lee M.A., Ryu K.H., Kim S.E., Yoo K. Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean J Intern Med 2008; 23 (1): 9—15.
  17. Wistrom J., Norrby S.R., Myhre E.B., Eriksson S., Granstrom G., Lagergren L., Englund G., Nord C.E., Svenungsson B. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47: 43—50.
  18. Hogenauer C., Hammer H.F., Krejs G.J., Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 1998; 27 (4): 702—710.
  19. Riggs M.M., Sethi A.K., Zabarsky T.F., Eckstein E.C., Jump R.L., Donskey C.J. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45: 992.
  20. Torres J., Jennische E., Lange S. Enterotoxins from Cl. difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut 1990; 31: 781—785.
  21. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390—397.
  22. Idem А. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189—193.
  23. Bulusu M., Narayan S., Shetler K., Triadafilopoulos G. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea. Am J Gastroenterol 2000; 95: 3137—3141.
  24. Manabe Y.C., Vinetz J.M., Moore R.D., Merz C., Charache P., Bartlett J.G. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 1995; 123: 835—840.
  25. Guerrant R.L. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001; 32: 331—351.
  26. Mylonakis E., Ryan E.T., Calderwood S.B. Clostridium difficile-associated diarrhea: a review. Arch Intern Med 2000; 161: 525—533.
  27. Laughon B.E., Viscidi R.P., Gdovin S.L., Yolken R.H., Bartlett J.G. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis 1984; 149: 781—788.
  28. Скворцов В.В. Дисбиоз кишечника и антибиотик-ассоциированная диарея, диагностика и лечение. Лечащий врач 2008; 2: 43—47.
  29. Teasley D.G., Gerding D.N., Olson M.M., Peterson L.R., Gebhard R.L., Schwartz M.J., Lee J.T. Jr. Prospective randomized trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet 1983; 2: 1043—1046.
  30. Wenisch C., Parschalk B., Hasenhundl M., Hirschl A.M., Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813—818.
  31. Bartlett J.G. Treatment of Clostridium difficile colitis. Gastroenterology 1985; 89: 1192—1195.
  32. John G.B. Antibiotic-associated diarrhea. New Engl J Med 2002; 5 (346): 334—339.
  33. Cartman S.T., Heap J.T., Kuehne S.A., Cockayne A., Minton N.P. The emergence of «hypervirulence» in Clostridium difficile. Int J Med Microbiol 2010; 300: 387—395.
  34. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Adv Gastroenterol 2011; 4 (3): 185—197.
  35. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., Pepin J., Wilcox M.H. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol 2010; 31 (5): 431—455.
  36. Surawicz C.M., Brandt L.J., Binion D.G., Ananthakrishnan A.N., Curry S.R., Gilligan P.H., McFarland L.V., Mellow M., Zuckerbraun B.S. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108 (4): 478—498.
  37. Garey K.W., Ghantoji S.S., Shah D.N., Habib M., Arora V., Jiang Z.D., DuPont H.L. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother 2011; 66 (12): 2850—2855.
  38. Vaughan R.B. The romantic rationalist: a study of Elie Metchnikoff. Med Hist 1965; 9: 201—215.
  39. Verna E.C., Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol 2010; 3 (5): 307—319.
  40. Воrchers A.T., Selmi C., Meyers F.J., Keen C.L., Gershwin M.E. Probiotics and immunity. J Gastroenterol 2009; 44: 26—46.
  41. Lin H.C. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292 (7): 852—858.
  42. Vanderpool C., Yan F., Polk D.B. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases Inflamm. Bowel Dis 2008; 14: 1585—1596.
  43. Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., Dubuquoy C., Merour E., Geboes K., Chamaillard M., Ouwehand A., Leyer G., Carcano D., Colombel J.F., Ardid D., Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35—37.
  44. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812—822.
  45. Szajewska H., Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther 2005; 22: 365—337.
  46. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., Gasbarrini A. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002; 16: 1461—1467.
  47. D’Souza AL., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324 (7350): 1361.
  48. Шульпекова Ю.О. Антибиотикассоциированная диарея. РМЖ 2007; 6 (15): 1—6.
  49. Маев И.В., Самсонов А.А., Плотникова Е.Ю., Никушкина И.Н., Ивашкина Н.Ю. Пробиотики и пребиотики в клинической практике. Фарматека 2011; 5 (218): 33—41.
  50. Горелов А.В., Усенко Д.В., Трефилова И.Ш. Профилактика антибиотикассоциированной диареи у детей, больных острыми респираторными заболеваниями. Инфекционные болезни 2008; 1: 69—72.
  51. Симаненков В.И., Ильяшевич И.Г., Коновалова Н.В. Пробиотическая терапия в комплексном лечении пневмонии. Врач 2010; 3: 46—49.
  52. Бельмер С.В. Антибиотик-ассоциированный дисбактериоз кишечника. РМЖ 2004; 12: 148—151.
  53. Щербаков П.Л., Нижевич А.А., Амирова В.Р. Антибиотик-ассоциированная диарея у детей — особенности коррекции микрофлоры. Вопр. практической педиатрии 2010: 5 (5): 44—51.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies